Price T Rowe Associates Inc. MD Sells 353,861 Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC)

Price T Rowe Associates Inc. MD trimmed its position in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 90.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,143 shares of the company's stock after selling 353,861 shares during the quarter. Price T Rowe Associates Inc. MD owned 0.05% of C4 Therapeutics worth $138,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Wasatch Advisors LP lifted its holdings in shares of C4 Therapeutics by 7.0% during the 4th quarter. Wasatch Advisors LP now owns 6,072,601 shares of the company's stock valued at $21,861,000 after buying an additional 395,233 shares during the period. Mariner LLC lifted its holdings in shares of C4 Therapeutics by 28.8% during the 4th quarter. Mariner LLC now owns 167,975 shares of the company's stock valued at $605,000 after buying an additional 37,564 shares during the period. Invesco Ltd. lifted its holdings in shares of C4 Therapeutics by 7.2% during the 4th quarter. Invesco Ltd. now owns 69,193 shares of the company's stock valued at $249,000 after buying an additional 4,647 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of C4 Therapeutics by 34.9% during the 4th quarter. Wells Fargo & Company MN now owns 36,306 shares of the company's stock valued at $131,000 after buying an additional 9,389 shares during the period. Finally, ExodusPoint Capital Management LP bought a new position in shares of C4 Therapeutics during the 4th quarter valued at $215,000. 78.81% of the stock is owned by institutional investors.

C4 Therapeutics Price Performance

NASDAQ:CCCC opened at $1.38 on Friday. The firm has a market capitalization of $97.99 million, a price-to-earnings ratio of -0.81 and a beta of 3.10. C4 Therapeutics, Inc. has a one year low of $1.09 and a one year high of $7.66. The business has a fifty day moving average price of $1.59 and a 200-day moving average price of $3.08.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.11. The firm had revenue of $7.20 million during the quarter, compared to analyst estimates of $3.54 million. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%. On average, equities research analysts expect that C4 Therapeutics, Inc. will post -1.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, UBS Group raised C4 Therapeutics to a "hold" rating in a report on Friday, February 14th.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.